下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Novavax (NASDAQ:NVAX) Price Target Cut to $110.00 by Analysts at Cowen
考恩的分析师将诺华(纳斯达克代码:NVAX)的目标价下调至110.00美元

kopsource ·  {{timeTz}}

Novavax (NASDAQ:NVAX – Get Rating) had its target price decreased by Cowen from $150.00 to $110.00 in a research report released on Tuesday, Stock Target Advisor reports.

据Stock Target Advisor报道,在周二发布的一份研究报告中,考恩将诺华公司(纳斯达克代码:NVAX-GET评级)的目标价从150.00美元下调至110.00美元。

A number of other equities research analysts have also recently weighed in on NVAX. Cowen dropped their price target on shares of Novavax from $150.00 to $110.00 and set an outperform rating for the company in a research report on Tuesday. Cantor Fitzgerald raised their price objective on shares of Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Bank of America started coverage on shares of Novavax in a research note on Friday, May 20th. They issued an underperform rating and a $35.00 price objective for the company. Finally, B. Riley lowered their price objective on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, Novavax currently has an average rating of Hold and a consensus target price of $151.00.

其他一些股票研究分析师最近也加入了对NVAX的看法。考恩在周二的一份研究报告中将诺瓦克斯的目标价从150.00美元下调至110.00美元,并为该公司设定了表现优于大盘的评级。康托·菲茨杰拉德在6月8日星期三的一份研究报告中将诺华公司股票的目标价从146.00美元上调至168.00美元。美国银行在5月20日星期五的一份研究报告中开始对Novavax的股票进行报道。他们发布了表现不佳的评级和35.00美元的公司目标价。最后,B.Riley在7月22日星期五的一份研究报告中将诺华的股票目标价从181.00美元下调至171.00美元。一名股票研究分析师对该股的评级为卖出,3名分析师对该股给予持有评级,5名分析师对该公司给予买入评级。根据MarketBeat的数据,诺华目前的平均评级为持有,共识目标价为151.00美元。

Get
到达
Novavax
诺华
alerts:
警报:

Novavax Price Performance

Novavax性价比

Shares of NVAX opened at $40.28 on Tuesday. Novavax has a 1-year low of $34.88 and a 1-year high of $277.80. The stock has a market cap of $3.15 billion, a PE ratio of -2.28, a P/E/G ratio of 0.06 and a beta of 1.52. The firm has a 50-day simple moving average of $53.49 and a two-hundred day simple moving average of $63.48.

周二,NVAX的股价开盘报40.28美元。诺华的一年低点为34.88美元,一年高位为277.80美元。该股市值为31.5亿美元,市盈率为-2.28,市盈率为0.06,贝塔系数为1.52。该公司的50日简单移动均线切入位在53.49美元,200日简单移动均线切入位在63.48美元。

Novavax (NASDAQ:NVAX – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing analysts' consensus estimates of $5.51 by ($12.04). Novavax had a negative net margin of 93.91% and a negative return on equity of 572.54%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business earned ($4.75) earnings per share. Novavax's revenue was down 37.6% on a year-over-year basis. As a group, sell-side analysts expect that Novavax will post 27.23 earnings per share for the current fiscal year.
诺华(纳斯达克代码:NVAX-GET Rating)上一次公布季度收益是在8月8日星期一。这家生物制药公司公布了本季度每股收益(6.53美元),低于分析师普遍预期的5.51美元(12.04美元)。诺华的净利润率为负93.91%,净资产回报率为负572.54%。该公司本季度营收为1.86亿美元,而分析师预期为10.2亿美元。在去年同一季度,该业务实现了每股收益(4.75美元)。Novavax的收入同比下降了37.6%。卖方分析师预计,作为一个整体,Novavax本财年的每股收益将达到27.23美元。

Institutional Inflows and Outflows

机构资金流入和流出

Institutional investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd purchased a new position in Novavax in the first quarter worth approximately $9,839,000. IFM Investors Pty Ltd lifted its stake in Novavax by 19.6% in the first quarter. IFM Investors Pty Ltd now owns 11,096 shares of the biopharmaceutical company's stock worth $817,000 after acquiring an additional 1,819 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its stake in Novavax by 8.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 13,990 shares of the biopharmaceutical company's stock worth $2,002,000 after acquiring an additional 1,100 shares during the last quarter. Banque Cantonale Vaudoise lifted its stake in Novavax by 3,018.2% in the first quarter. Banque Cantonale Vaudoise now owns 11,631 shares of the biopharmaceutical company's stock worth $857,000 after acquiring an additional 11,258 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Novavax by 2.2% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 178,351 shares of the biopharmaceutical company's stock worth $13,136,000 after acquiring an additional 3,814 shares during the last quarter. Hedge funds and other institutional investors own 43.91% of the company's stock.

机构投资者最近增持或减持了该公司的股份。Qube Research&Technologies Ltd在第一季度购买了Novavax的一个新头寸,价值约983.9万美元。IFM Investors Pty Ltd在第一季度增持了19.6%的Novavax股份。IFM Investors Pty Ltd在上个季度增持了1,819股后,现在拥有这家生物制药公司11,096股股票,价值817,000美元。野村资产管理有限公司(Nomura Asset Management Co.Ltd.)第四季度增持Novavax股份8.5%。野村资产管理有限公司(Nomura Asset Management Co.Ltd.)在上个季度增持了1,100股野村资产管理公司(Nomura Asset Management Co.)股票后,目前持有这家生物制药公司13,990股股票,价值2,002,000美元。第一季度,Canonale Vaudoise银行增持了Novavax 3018.2%的股份。Canonale Vaudoise银行现在拥有这家生物制药公司11631股票,价值85.7万美元,在上个季度额外购买了11258股。最后,三井住友信托控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)在第一季度增持了Novavax 2.2%的股份。三井住友信托控股有限公司(Sumitomo Mitsui Trust Holdings Inc.)目前持有这家生物制药公司178,351股股票,价值13,136,000美元,该公司在上个季度增持了3,814股股票。对冲基金和其他机构投资者持有该公司43.91%的股份。

About Novavax

关于Novavax

(Get Rating)

(获取评级)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Novavax,Inc.是一家生物技术公司,专注于疫苗的发现、开发和商业化,以预防严重的传染病和满足卫生需求。该公司的候选疫苗包括冠状病毒候选疫苗NVX-CoV2373,它正在进行两项第三阶段试验、一项IIb阶段试验和一项I/II阶段试验;NanoFlu,一种处于第三阶段临床试验的季节性四价流感疫苗候选产品;以及ResVax,一种呼吸道合胞病毒(RSV)融合(F)蛋白质纳米颗粒疫苗候选产品。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Novavax (NVAX)
  • Are 3M, Honeywell, GE Buys After Quarterly Reports?
  • This Defense Stock Has Bullish Fundamentals AND Technicals
  • CVS and Walgreens Show Why Investment Objectives Matter
  • Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
  • Are Medtronic And Intuitive Surgical Poised For Big Growth?
  • 免费获取StockNews.com关于Novavax的研究报告(NVAX)
  • 3M、霍尼韦尔、通用电气在季度报告后收购吗?
  • 这只国防股票的基本面和技术面都看涨
  • CVS和Walgreens展示为什么投资目标很重要
  • 索菲金融股票终于准备好为投资者买单了吗?
  • 美敦力和直觉外科公司准备实现大增长吗?

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

接受Novavax Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Novavax和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部